https://www.vernalis.com/research/myeloid-cell-leukemia-1-mcl-1-in-vivo-active-inhibitor/2024-05-03T10:54:52+00:00https://www.vernalis.com/research/heat-shock-protein-90-hsp90-phase-ii-candidate/2024-06-21T09:59:02+00:00https://www.vernalis.com/research/checkpoint-kinase-1-chk1-pre-clinical-candidate/2024-05-03T10:51:27+00:00https://www.vernalis.com/research/b-cell-lymphoma-2-bcl-2-phase-i-clinical-candidate/2024-05-03T10:59:58+00:00https://www.vernalis.com/research/hsp90-oral-backup-pre-clinical-candidate/2024-06-11T08:58:02+00:00https://www.vernalis.com/research/pyruvate-dehydrogenase-kinase-pdhk-application-of-off-rate-screening-in-the-identification-of-novel-pan-isoform-inhibitors/2024-05-03T11:09:12+00:00https://www.vernalis.com/research/design-of-leucine-rich-repeat-kinase-2-lrrk2-inhibitors-using-a-crystallographic-surrogate-derived-from-checkpoint-kinase-1-chk1/2024-05-03T11:13:35+00:00https://www.vernalis.com/research/fragment-based-discovery-of-novel-non-hydroxamate-lpxc-inhibitors-with-antibacterial-activity/2024-05-03T11:15:31+00:00https://www.vernalis.com/research/fragment-derived-selective-inhibitors-of-dual-specificity-kinases-dyrk1a-and-dyrk1b/2024-05-03T11:19:05+00:00